AzTrials
AzTrials

SpondylarthritisNCT05926453

Assessment of Cardiorespiratory Fitness in Spondylarthritis

An observational study of Spondylarthritis, run by Diakonhjemmet Hospital at 1 site in Norway.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Spondyloarthritis is a chronic inflammatory joint disease that affects the spine and sacroiliac joints. Most untreated patients eventually experience impaired mobility of the spine, pain and reduced physical function. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Spondylarthritis
What is being tested?
Maximal cardiorespiratory exercise test
How many people
55 participants
Where
1 siteNorway
Study dates
17 Oct 2023to 1 Jun 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with spondylarthritis diagnosed by a rheumatologist

Who may be able to join

  • Adult patients 18-70 years old with axial SpA according to ASAS criteria

Who cannot join

  • The American College of Sports Medicine (ACSM) have listed the following contradictions to CPET and participants with absolute or relative contradictions will be excluded.
  • Absolute contraindications to max CPET: acute myocardial infarction within 2 days, unstable angina, uncontrolled cardiac arrhythmia with hemodynamic compromise, active endocarditis, symptomatic severe aortic stenosis, decompensated heart failure, acute pulmonary embolism, pulmonary infarction, or deep venous thrombosis, acute myocarditis or pericarditis, suspected or known aneurysm, acute systemic infection accompanied by fever, body aches, or swollen lymph glands.
  • Relative contraindications to max CPET: Left main coronary stenosis, moderate to severe aortic stenosis, arrhythmia (tachydysrhythmia or bradyarrhythmia), recent stroke or transient ischemic attack, resting hypertension with blood pressure systolic > 200 mmHg and/or diastolic > 115 mmHg, uncorrected medical conditions, such as significant anaemia, important electrolyte abnormalities imbalance, and hyperthyroidism, uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis or myxoedema) and chronic infectious disease (e.g. mononucleosis, hepatitis, AIDS).
  • For the SpA population we have included the following specific exclusion criteria: Unable to walk for less than 15 minutes without support, pregnancy, active uveitis, under- or overweight (BMI: ≤ 18.5 or > 40)

Trial locations and contacts

1 site in 1 country.

Norway1 site
  • Diakonhjemmet hospital

    Oslo

Other trials in Norway

About this study

Official title: Validation of Indirect Estimation Against Direct Gas Measurements of Cardiorespiratory Fitness Using the Modified Balke Protocol on a Treadmill in Patients With Spondylarthritis

Spondyloarthritis is a chronic inflammatory joint disease that affects the spine and sacroiliac joints. Most untreated patients eventually experience impaired mobility of the spine, pain and reduced physical function. Exercise is a cornerstone in the treatment of patients with spondylarthritis and it has been shown that high intensity exercise is just as effective in reducing disease activity as immunosuppressive medication. Additionally, patients with spondylarthritis have increased risk of cardiovascular disease both due to traditionally risk factors (obesity, high blood pressure etc) but also due to chronic inflammation. A maximal cardiopulmonary exercise test (CPET) is a measure of cardiorespiratory fitness that can be used to show progression of the exercise and which also is correlated to all-cause mortality and life expectancy.

The investigators will validate an indirect maximal CPET against the gold standard with direct gas exchange measurements in patients with spondylarthritis. The indirect test is less time consuming, requires less sophisticated equipment, has lesser requirements to test personnel and facilities, and has less expenditures than the direct test. With a validated indirect maximal CPET the test of cardiorespiratory fitness will be more accessible for patients with spondylarthritis both in-hospital but also municipal.

Read the detailed description

Spondylarthritis (SpA) is a chronic inflammatory disease which affects sacroiliac joints, spine and peripheral joints with an onset usually before the age of 45 years. The prevalence is approximately 1.5% and correlated to the distribution of the genotype HLA-B27 in the population. Most untreated patients eventually experience limited mobility of the spine, pain, reduced physical function and fatigue. There is a considerable likelihood for significantly impaired quality-of-life, morbidity and work disability. Exercise is a cornerstone in the treatment of patients with SpA, and it has been shown that supervised high intensity interval training has equally positive effect on disease activity as biological immunomodulating treatment. The inflammatory joint diseases have a high prevalence of comorbidities such as cardiovascular disease (CVD) driven by both traditional and non-traditional risk factors. The CVDs are an important cause of premature mortality for patients with inflammatory joint diseases including SpA.. Traditional CVD risk factors such as obesity and lower levels of physical activity, coupled with non-traditional risk factors such as systemic inflammation, are key causal factors.

Cardiorespiratory fitness is a strong predictor of all-cause mortality and life expectancy also for patients with SpA, and improved cardiorespiratory fitness seems to reduce the risk of cardiovascular disease in a quantitative manner. The gold standard for measurement of an individual's cardiopulmonary fitness expressed as the peak oxygen consumption (VO2peak) is considered as the direct gas exchange measurements during maximal exercise of large muscle groups such as running, cycling, or swimming. However, the direct gas exchange measurement is time-consuming and requires technical instrumentation and highly skilled personnel, and it is therefore often more convenient to use estimates. For the maximal exercise test to measure correct VO2peak levels or estimate correct physical fitness the participants must be willing and capable of pushing themselves with the assistance of cheering from the technical personnel otherwise the VO2peak will be underestimated. It is therefore evident that the result of the performed test depends on the maximal effort being executed.

The modified Balke protocol is a protocol often used in maximal cardiopulmonary exercise testing (CPET) on a treadmill. According to this protocol the workload is increased by elevated inclination to a maximum of 15%. If the participant is capable of further increased workload the speed of the treadmill is increased till exhaustion of the participant. With the indirect test, VO2peak is estimated from the time to exhaustion (TTE), incline of the treadmill and the speed of the treadmill. The indirect test requires a treadmill with adjustable incline, heart rate monitor and a stopwatch. The direct VO2 measurement is performed with breath-by-breath gas exchange measurement of inspiratory and expiratory air by a Hans Rudolph mask and direct analysis using an ergospirometer system. The direct gas measurements require expensive and sophisticated equipment as well as trained personnel to perform the test, and this is not standard in many of the out-patient clinics. Thus, the indirect test is cheaper and less time-consuming for the participant and the health personnel making it a more accessible test of cardiorespiratory fitness than the directly measured gas exchange. The indirect estimate of physical performance has, to our knowledge, not yet been validated against the direct gas measurement using the modified Balke protocol in patients with SpA.

Hypothesis and research question The investigators hypothesise that the estimated VO2peak from the maximal CPET is well correlated to the VO2peak measured by direct gas measurements in patients with SpA.

Tests Modified Balke protocol for maximal CPET All participants are asked not to eat for 2-hours prior to the test and to empty their bladder right before the start of measurements. Ahead of the CPET, participants will be familiarised with treadmill walking with a warm-up of 5 minutes at a 1.5% incline. The output setting for the CPET is 4.5% incline and an estimated output level (unfit woman 4.3 km*h-1; unfit man/normal woman 4.7 km*h-1; fit woman/normal man 5.3 km*h-1; fit man 5.3 km*h-1). The incline is increased with 2% every minute, when an incline of 15% is reached the pace of the treadmill is increased with 0.3 km*h-1 every minute while the inclination is kept constant (15%) until participant exhaustion. The test is complete when the participants reach their exhaustion point and are unable to continue the test despite verbal encouragement from the test technician. The protocol is terminated in advance of exhaustion if the test technician observes abnormal and/or adverse test values or the patient requests to stop. Borg RPE ≥ 18, VO2 plateau (two averaged 30-second consecutive measures), age and gender specific reference values for respiratory exchange ratio, blood lactate above age references and the maximal heart rate within 90% of the age-predicted maximum (211-(0.64*age) are used to validate the CPET as a maximal CPET at test termination. Participants who do not fulfil at least 2 of the 4 requirements will be excluded from analyses.

Calculations

For the indirect estimates the maximal CPET data TTE, inclination, and speed is used for calculations of VO2peak. There will use two equations for indirect calculations:

The ACSM equation:

VO2peak = (0.1 * speed (m*s-1) + (1.8 * speed(m*s-1) * inclination (%)) + 3.5

The HUNT3 equation:

Men: 24.24 + (0.599 * inclination) + (3.97 * speed) - (0.122 * body weight) - (0.126 * age) Women: 17.21 + (0.582 * inclination) + (3.317 * speed) - (0.116 * body weight) - (0.099 * age) The two formulas will be compared and validate these calculations against the direct CPET and the non-exercise formula from Kondiskalkulatoren (World Fitness Level).

Measurements The CPET will be performed on a treadmill with 12-lead ECG and scaled by the modified Borg RPE (6-20). Blood pressure is measured before test start (mmHg) and every other minute throughout the test. Heart rate is measured continuously during the CPET and Borg RPE is reported every minute. HRpeak is registered together with the time point of its occurrence. Before the CPET height (m), body weight (kg) and circumference of hip (cm) and waist (cm) are measured. Body composition is measured by bioelectrical impedance analysis (BIA).

Pulmonary function will be assessed by spirometer according to guidelines, and forced expiratory volume (FEV1 L), forced vital capacity (L) and peak expiratory flow (L/min) will be recorded from three attempts at maximal expiratory flow volume loops. Maximal voluntary ventilation (MVV, L/min) will be measured twice by breathing deeply and rapidly for 12 seconds. In cases of poor technique, MVV will be estimated as FEV1 * 37.5. Gas exchange is measured through a Hans Rudolph two-way mask using a breath-by-breath gas analysing system. VO2max is defined as the plateau VO2 of two 30-second samples and the VO2peak is defined as the highest VO2 measured during the test.

Blood lactate concentration is measured in a small blood sample from the fingertip within 60 seconds of test completion to evaluate level of anaerobic processes. CRP is measured in a small blood sample from the fingertip before the CPET for ASDAS calculations.

Being tested
Maximal cardiorespiratory exercise test
Keywords
exercise test, validation study
Medical subject headings
Spondylarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Maximal cardiorespiratory exercise testOther

    previously described

Study groups in NCT05926453
Study groupRoleWhat they receive
Maximal CPETOne maximal cardiopulmonary exercise test with simultaneous registration of direct gas measurements and the variables necessary for estimated cardiorespiratory fitness.
Receives: Other: Maximal cardiorespiratory exercise test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation coefficient between VO2peak direct gas measurement and estimated VO2peak ml/minute/kilogram using the modified Balke protocol

    Comparison between the gold standard measurement og cardiorespiratory fitness and the indirect measurements.

    Measured: 2 hours

Secondary outcomes (9)
  1. Correlation coefficient between VO2peak direct gas measurement and estimated VO2peak ml/minute using the modified Balke protocol

    Comparison between the gold standard measurement og cardiorespiratory fitness and the indirect measurements - not weight adjusted

    Measured: 2 hours

  2. Performance validation criteria

    To ensure that the participants have performed to their maximal capacity the Borg RPE will be evaluated.

    Measured: 2 hours

  3. Performance validation criteria

    To ensure that the participants have performed to their maximal capacity the maximal pulse will be evaluated.

    Measured: 2 hours

  4. Performance validation criteria

    To ensure that the participants have performed to their maximal capacity the lactate level will be evaluated.

    Measured: 2 hours

  5. Performance validation criteria

    To ensure that the participants have performed to their maximal capacity the expiratory exchange ratio will be evaluated.

    Measured: 2 hours

  6. Testing non-exercise calculation of physical fitness and two different formulas for indirect calculations

    The HUNT calculations a gender specific, and will be compared to the ACSM calculations Men: 24.24 + (0.599 * inclination) + (3.97 * speed) - (0.122 * body weight) - (0.126 * age) Women: 17.21 + (0.582 * inclination) + (3.317 * speed) - (0.116 * body weight) - (0.099 * age)

    Measured: 2 hours

  7. Testing non-exercise calculation of physical fitness and two different formulas for indirect calculations

    The ACSM calculation will be compared to the HUNT calculation

    Measured: 2 hours

  8. Safety measures

    electro cardiogram will be performed prior to and during the exercise test to assess cardiac ischemia (T wave inversion og ST depression > 2 mm) or pathological arrythmia (blockage)

    Measured: 2 hours

  9. Safety measures

    blood pressure will be performed prior to and during the exercise test to observe for malignant hypertension

    Measured: 2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jul 2023
  2. Study start17 Oct 2023
  3. Primary completion9 Jul 2024
  4. Study completion1 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case crossover
Time perspective
Cross-sectional
Enrolment
55 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05926453
Sponsor's protocol ID
DS-00772
Status last verified
Aug 2026
First submitted
12 Jun 2023
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Spondylarthritis, run by Diakonhjemmet Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation coefficient between VO2peak direct gas measurement and estimated VO2peak ml/minute/kilogram using the modified Balke protocol (time frame: 2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in